Pfizer Inc. said participants were showing mild-to-moderate side effects when given either the company’s experimental coronavirus vaccine or a placebo in an ongoing late-stage study.

Gilead remdesivir study finds only marginal benefit for moderate COVID-19 patients (Reuters) – Moderately ill COVID-19 patients saw their condition improve after a 5-day course of Gilead Sciences Inc’s (GILD.O) remdesivir, but the drug did not significantly shorten hospital stays and a 10-day course did not show a benefit, according to new data. The drug, […]

The U.S. Food and Drug Administration will review GlaxoSmithKline’s experimental treatment for multiple myeloma, a common form of blood cancer, for a reported side effect which affects the eyes of patients.

Dr. Reddy’s Laboratories’ Foram Vaishnav discusses the role and impact of pharmacovigilance in the pharmaceutical industry.

Johnson & Johnson’s drug Balversa won U.S. approval as the first targeted therapy for advanced bladder cancer, the Food and Drug Administration announced.

Roche’s seven-year-old rheumatoid arthritis drug Actemra is being linked to hundreds of deaths due to undisclosed side effects.

(Reuters Health) – According to a reanalysis of the original data from a 2001 study of paroxetine (Paxil) for teens with major depression, the drug was not effective and led to serious side effects, which is not how the results were presented 14 years ago. “There have been warnings about paroxetine for a long time,” […]

A medical journal criticized British drugmaker GlaxoSmithKline on Thursday for delaying access to key data from a trial of its antidepressant Seroxat that would have shown earlier that it is neither safe or effective in adolescents.   The widely used medicine, known generically as paroxetine, is linked to an increased risk of suicide in young people […]

Still no Rx for patient adherence Pharma limited in what it can do, but can still have a positive impact   Patient adherence remains a complex puzzle with no simple solutions, and no one stakeholder involved – physicians, insurers, or pharmaceutical companies – can provide all the answers needed. Even though the influence of pharma […]

SEATTLE, Aug. 4, 2015 /PRNewswire/ — Dr. Keesha Ewers of The Functional Sexology Institute states the potential FDA approval of flibanserin, or what is being touted as “pink Viagra,” sets women and the treatment of decreased female sexual desire back several decades. Diminished libido in women has many root causes and addressing libido as a singular […]